Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool January 3, 2005 Nathan Slaughter	Walgreen Seeing Green Rivals CVS and Rite Aid have a bitter pill to swallow as Walgreen stays strong. While Walgreen's revenues were in line with forecasts, the stronger-than-expected bottom line has the stock gaining ground.
The Motley Fool June 28, 2005 Mike Cianciolo	Just What Investors Prescribed With another quarter of stellar growth at Walgreen, the stock approaches its highest price ever.
The Motley Fool September 26, 2006 Ryan Fuhrmann	Jaw-Dropping Pill-Popping at Walgreen How much longer can investors count on Walgreen's stellar numbers?
The Motley Fool October 4, 2005 Seth Jayson	Same Old Same-Store Story Reports from Walgreen and Rite Aid confirm the obvious. Investors will nearly always do better buying the best company in any given space.
The Motley Fool January 5, 2004 Jeff Hwang	Prescriptions Boost Walgreen Earnings and sales bumped by early flu season and improved non-pharmacy sales.
The Motley Fool August 15, 2005 Bobby Shethia	Walgreen's Prescription for Success The drugstore chain's smart and steady growth makes it a good choice for investors.
The Motley Fool March 28, 2005 Alyce Lomax	A Cool Quarter for Walgreen Are second-quarter earnings putting a damper on Walgreen?
The Motley Fool December 26, 2006 Matthew Crews	Walgreen Represents This drugstore business has proven itself; does its stock match up?
The Motley Fool July 6, 2004 Alyce Lomax	Not Ready for Rite Aid Can the drugstore chain hold a candle to the competition? Its shares are trading at 22 times forward earnings, making it a seemingly less-than-advantageous time to place a bet on them.
The Motley Fool January 3, 2006 Stephen D. Simpson	Walgreen Reaps Rewards of Rx The nation's top pharmacy keeps on rolling, but investors might want to keep an eye on the new ventures.
The Motley Fool October 2, 2007 Lawrence A. Rothman	Can the Right Prescription Heal Walgreen? Walgreen is suffering from heightened competition, expenses rising more than 11%, and the company itself predicting its challenges will probably continue into the near future.
The Motley Fool September 28, 2007 Timothy M. Otte	Foolish Forecast: Walgreen Still Minting the Green? In advance of fourth-quarter earnings, analysts expect the company to continue its record of four straight years of sales growth.
The Motley Fool June 26, 2007 Ryan Fuhrmann	Walgreen Sells Convenience Walgreen continues to grow market share, with little sign of slowing down.
The Motley Fool June 2, 2004 Alyce Lomax	Walgreen's Mellow May Will the drugstore chain get a taste of its own medicine?
The Motley Fool September 21, 2006 Vitaliy Katsenelson	Don't Hit the Panic Button Just Yet Wall Street plays the overreacting game; Walgreen and CVS suffer. These stocks have big tailwinds behind them.
The Motley Fool March 22, 2004 Alyce Lomax	Walgreen's Green Quarter Investors take an earnings miss to heart. But the future looks good.
The Motley Fool September 27, 2004 Phil Wohl	Walgreen: Prescription for Success The leading drugstore retailer is leveraging prescription sales to produce record results. Fourth-quarter earnings grew to $0.32 per share, which was an 18% improvement over last year's $0.27.
The Motley Fool July 6, 2007 Timothy M. Otte	Drugstore Sales Remain Healthy The big four drugstore chains report higher comparable sales in June. Walgreen... CVS... Rite Aid... Long's...
The Motley Fool April 9, 2007 Mike Cianciolo	CVS: Continued Vigorous Sales The drugstore chain grows sales and itself in March. Investors, take note.
The Motley Fool October 6, 2010 Rich Smith	This Just In: Upgrades and Downgrades Jefferies on Walgreen: Take two shares and thank me in the morning.
The Motley Fool July 5, 2005 Alyce Lomax	Business As Usual at Walgreen Walgreen's same-store sales for June certainly don't disappoint. Investors might question whether the retail pharmacy can keep up the great work.
The Motley Fool February 2, 2005 Alyce Lomax	CVS's Shot in the Arm Buying the Eckerd drugstore chain from J.C. Penney was apparently a good move for CVS. It continues to benefit from the purchase, reporting positive earnings and beating analysts' expectations by a penny.
The Motley Fool September 14, 2006 Ryan Fuhrmann	Playing Defense With the Drugstore Industry Retail pharmacy August sales trends help investors discern the leader in this appealing sector.
The Motley Fool February 16, 2005 Brian Gorman	Medco's Double-Edged Sword The pharmacy benefit manager's latest financial report indicates that its business remains robust. But is it at the expense of retail pharmacies?
The Motley Fool October 7, 2010	DRIP Portfolio Candidate: Walgreen Why this nationally known drugstore should make it into your DRIP portfolio.
The Motley Fool October 8, 2011 Shubh Datta	Impasse Hurts Walgreen's Quarter Walgreen posted a staggering 69% earnings jump but still saw its shares slide.
The Motley Fool September 22, 2006 Ryan Fuhrmann	More in Store at Rite Aid? The retail pharmacy posted strong second-quarter sales, and an acquisition could help long-term results. Investors, take note.
The Motley Fool October 6, 2004 Steven Mallas	Walgreen Getting Greener The retail pharmacy's comps for September are once again healthy. Capital growth is the focus of the total return on this stock, making the dividend payout more of an indicator than a palpable engine of appreciation at this stage.
The Motley Fool July 6, 2007 Lawrence Rothman	Walgreen Does It Again The company continues to impress, posting positive same-store sales results month after month. At a P/E of 21, this stock isn't especially rich, given the solid performance that the company delivers.
The Motley Fool September 29, 2010 Andrew Bond	Walgreen Surprises the Experts Walgreen posts a great quarter as competition falters.
The Motley Fool June 6, 2006 Ryan Fuhrmann	Harry's Happy With Walgreen Walgreen acquires the Happy Harry's pharmacy chain. Investors, take note.
The Motley Fool August 16, 2007 Lawrence Rothman	Longs' Prescription for Success Longs Drug Stores may be small, but it excels in its regional niche. Operating primarily on the West Coast, second-quarter results show a company with lots of room for growth.
The Motley Fool September 23, 2005 Stephen D. Simpson	Waiting for Walgreen Earnings that disappoint Wall Street could be long-term investors' golden opportunity. Let's look toward Walgreen's earnings release next week and see if an opportunity will present itself.
The Motley Fool June 10, 2004 Alyce Lomax	Summer Starts at CVS The drugstore company releases same-store sales results on the cusp of its Eckerd acquisition.
The Motley Fool June 24, 2011 Shubh Datta	A Big Question Looms for Walgreen Strong quarterly results enable the company to maintain its annual outlook, but a breakup costs dearly in the short term.
The Motley Fool June 25, 2004 Steven Mallas	Rite Aid in the Shadows The first quarter for Rite Aid, the pharmaceutical retailer, shows a profit, but is it time to add this stock to your portfolio?
The Motley Fool June 22, 2006 Stephen D. Simpson	Rite Aid: Not Quite Rad, but Not All Bad Better results are possible, but there might be better ideas for investors.
The Motley Fool June 11, 2007 Mike Cianciolo	Rite Aid's Generic Sales The drugstore chain gradually increases sales, and catches up to the big boys in one way. Investors, take note.
The Motley Fool June 23, 2006 Rich Smith	Foolish Forecast: Walgreen The retail pharmacy reports its fiscal third-quarter 2006 earnings on Monday. Investors -- buy, sell or waffle?
The Motley Fool January 5, 2007 Matthew Crews	Rite Aid's Baby Steps If Rite Aid does manage 5% operating margins, this pharmacy chain's shares will get the love they deserve.
The Motley Fool April 4, 2007 Timothy M. Otte	Walgreen's Comp Machine The drugstore operator steams through March with 8% comparable sales growth. The stock trades at a P/E of 24 times trailing-12-month earnings, about one-third higher than the average of all S&P 500 companies.
The Motley Fool November 16, 2006 Matthew Crews	Medicare Benefits for Longs Drug Stores Part D benefit services generate sales for the retail pharmacy, but the store faces larger rivals. Investors, take note.
The Motley Fool March 26, 2007 Ryan Fuhrmann	Addicted to Growth at Walgreen Walgreen is a steady grower, but that comes at a price. Investors, take note.
The Motley Fool April 13, 2007 Ryan Fuhrmann	Rite Aid's Right-Size Ambitions If the retail pharmacy chain can improve its net margins, reduce debt, and smoothly integrate its latest acquisition, the stock's upside would be substantial.
The Motley Fool December 21, 2007 Timothy M. Otte	Walgreen Shapes Up for 2008 The drugstore chain reports lower expenses in the first quarter while pumping up sales.
The Motley Fool January 7, 2010 Gerard Torres	Walgreen Lives to Fight Another Day Despite recent success, Walgreen continues to face stiff competition.
The Motley Fool September 22, 2005 Stephen D. Simpson	Rite Aid Not Right Yet The bleeding seems to have stopped at this pharmacy, but recovery could be a long and slow road. Intrepid, not to mention patient, investors may see potential here, but there are far better turnaround ideas to be had.
The Motley Fool January 4, 2005 Seth Jayson	Rite Aid Still Needs First Aid Sales keep slacking for this tough turnaround. This doesn't mean investors should necessarily jump ship.
The Motley Fool April 29, 2010 Brian Orelli	A Prescription to Investigate Further Let's not worry just yet about Medco's margins.
The Motley Fool March 24, 2011 Rick Aristotle Munarriz	It's a Dot-Com Drug Deal Gone Bad The drugstore giant acquires the drugstore.com pipsqueak.